Mont-Saint-Guibert, Belgium, May 9, 2016 – Promethera Biosciences SA, a Belgian biotechnology company developing stem cell therapies for the treatment of inborn liver metabolic diseases (ILMD) and acquired liver diseases with high unmet medical needs, today announces that Dr John Tchelingerian, Chief Executive Officer, Promethera, will present and participate at two forthcoming leading international biotech conferences.
The conferences are BioEquity Europe 2016 in Copenhagen, Denmark and the World Stem Cell congress 2016 in London, UK.
John Tchelingerian will present at the 17th BioEquity Europe 2016 in Copenhagen, Denmark on 10 May, room 3 at 5:40pm CEST. John will provide updates about the development of Promethera’s product pipeline as well as providing important information about the company following their acquisition of the key assets of their most advanced competitor, the liver cell therapy company Cytonet and what this means for the strategy of Promethera. BioEquity Europe is designed for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for pharmaceutical licensing professionals to assess top prospects.
John Tchelingerian will also participate at a round table at the World Stem Cell congress 2016 at 11.25am on May 19, at the Business Design Centre in London. The roundtable will be entitled ‘Biotech updates: From head-to-toe’. The roundtable is set to provide updates on the latest biotech advances in cell therapy. Promethera Biosciences has been selected to represent the liver cell therapy area.
"Already since 2015 and even more in 2016, Promethera has driven forward considerably, following the timescale of the new strategic plan I designed when becoming CEO in 2015. This has culminated in the acquisition of the key assets of Cytonet. This adds a pre-commercialisation product, Heparesc(R) to our existing pipeline with HepaStem and H2Stem,as well as US presence to Promethera in Durham, NC, as well as additional senior management experience and capabilities,” said Dr. John Tchelingerian, CEO of Promethera. “It is of value for us now to update the market and investors on how we plan to continue to move forward to deliver critically needed therapies in the liver area to patients as soon as possible.”
About Promethera Biosciences
Promethera is a clinical stage biopharmaceutical company and the global leader and most advanced cell therapy and regenerative medicine company for the treatment of inborn and acquired liver diseases with no effective therapeutic cure. Promethera uses allogeneic progenitor cells, stem cells and mature hepatocytes harvested and purified from non-transplantable, healthy human livers (Heterologous Human Adult Liver-derived Progenitor Cells, HHALPC and Heterologous Human Liver Cells, HHLivC). Using its three different cell products, Heparesc(R) (mature hepatocytes), HepaStem and H2Stem (progenitor/stem cells), Promethera develops therapeutic options for the treatment of a broad variety of liver diseases ranging from orphan indications, such as rare inborn metabolic diseases including urea cycle disorders (UCD) or inherited diseases such a1at deficiency (a1-antitrypsin) and hemophilia to large indications such as acute on chronic liver failure (ACLF), fibrosis, nonalcoholic steatohepatits (NASH). Heparesc(R) is a pre-commercial product candidate that has been studied in two open multi-center clinical trials to evaluate the safety and efficacy in children with neonatal urea cycle defects. The Company is preparing for a new drug submission (NDS) for Heparesc(R) with Health Canada and a potential commercial launch of Heparesc(R) in selected countries. HepaStem successfully completed a phase I/II clinical study in UCD and Crigler-Najjar syndrome (CNS) and is currently in phase II clinical study in UCD patients under 12 years old. Further, HepaStem will be positioned based on its mesenchymal cell (MSC) features in acquired liver diseases by end of 2016 for a phase II safety clinical trial in ACLF. H2Stem a follow-on progenitor / stem cell with hepato-biliary features will enter the clinical stage in 2017 and target inborn metabolic diseases or inherited diseases such a1at deficiency. Founded in 2009 by Prof Etienne Sokal and the tech transfer office (TTO) of Université Catholique de Louvain, Sopartec, Promethera Biosciences is a spin-off of the Walloon Region-based Université Catholique de Louvain (UCL). With headquarters located in Mont-Saint-Guibert, Walloon Region, Belgium and a U.S. based GMP compliant manufacturing facility in Durham, NC, Promethera Biosciences has approximately 56 employees led by an experienced and international management team.
The conferences are BioEquity Europe 2016 in Copenhagen, Denmark and the World Stem Cell congress 2016 in London, UK.
John Tchelingerian will present at the 17th BioEquity Europe 2016 in Copenhagen, Denmark on 10 May, room 3 at 5:40pm CEST. John will provide updates about the development of Promethera’s product pipeline as well as providing important information about the company following their acquisition of the key assets of their most advanced competitor, the liver cell therapy company Cytonet and what this means for the strategy of Promethera. BioEquity Europe is designed for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for pharmaceutical licensing professionals to assess top prospects.
John Tchelingerian will also participate at a round table at the World Stem Cell congress 2016 at 11.25am on May 19, at the Business Design Centre in London. The roundtable will be entitled ‘Biotech updates: From head-to-toe’. The roundtable is set to provide updates on the latest biotech advances in cell therapy. Promethera Biosciences has been selected to represent the liver cell therapy area.
"Already since 2015 and even more in 2016, Promethera has driven forward considerably, following the timescale of the new strategic plan I designed when becoming CEO in 2015. This has culminated in the acquisition of the key assets of Cytonet. This adds a pre-commercialisation product, Heparesc(R) to our existing pipeline with HepaStem and H2Stem,as well as US presence to Promethera in Durham, NC, as well as additional senior management experience and capabilities,” said Dr. John Tchelingerian, CEO of Promethera. “It is of value for us now to update the market and investors on how we plan to continue to move forward to deliver critically needed therapies in the liver area to patients as soon as possible.”
About Promethera Biosciences
Promethera is a clinical stage biopharmaceutical company and the global leader and most advanced cell therapy and regenerative medicine company for the treatment of inborn and acquired liver diseases with no effective therapeutic cure. Promethera uses allogeneic progenitor cells, stem cells and mature hepatocytes harvested and purified from non-transplantable, healthy human livers (Heterologous Human Adult Liver-derived Progenitor Cells, HHALPC and Heterologous Human Liver Cells, HHLivC). Using its three different cell products, Heparesc(R) (mature hepatocytes), HepaStem and H2Stem (progenitor/stem cells), Promethera develops therapeutic options for the treatment of a broad variety of liver diseases ranging from orphan indications, such as rare inborn metabolic diseases including urea cycle disorders (UCD) or inherited diseases such a1at deficiency (a1-antitrypsin) and hemophilia to large indications such as acute on chronic liver failure (ACLF), fibrosis, nonalcoholic steatohepatits (NASH). Heparesc(R) is a pre-commercial product candidate that has been studied in two open multi-center clinical trials to evaluate the safety and efficacy in children with neonatal urea cycle defects. The Company is preparing for a new drug submission (NDS) for Heparesc(R) with Health Canada and a potential commercial launch of Heparesc(R) in selected countries. HepaStem successfully completed a phase I/II clinical study in UCD and Crigler-Najjar syndrome (CNS) and is currently in phase II clinical study in UCD patients under 12 years old. Further, HepaStem will be positioned based on its mesenchymal cell (MSC) features in acquired liver diseases by end of 2016 for a phase II safety clinical trial in ACLF. H2Stem a follow-on progenitor / stem cell with hepato-biliary features will enter the clinical stage in 2017 and target inborn metabolic diseases or inherited diseases such a1at deficiency. Founded in 2009 by Prof Etienne Sokal and the tech transfer office (TTO) of Université Catholique de Louvain, Sopartec, Promethera Biosciences is a spin-off of the Walloon Region-based Université Catholique de Louvain (UCL). With headquarters located in Mont-Saint-Guibert, Walloon Region, Belgium and a U.S. based GMP compliant manufacturing facility in Durham, NC, Promethera Biosciences has approximately 56 employees led by an experienced and international management team.
